SimBioSys has entered a strategic distribution agreement with Ricoh 3D for Healthcare to expand access to its TumorSight Viz solution.
TumorSight Viz is an artificial intelligence (AI)-driven surgical visualisation platform designed to support breast cancer surgeries.
It is designed to transform standard breast MRI (magnetic resonance imaging) into 3D visualisations to improve surgical decision-making.
The 3D surgical visualisation platform (version 1.3) has received the US Food and Drug Administration (FDA) clearance for breast cancer.
The partnership aims to speed up the adoption of the TumorSight Viz platform in breast cancer care.
Ricoh’s healthcare expertise and network will help bring the technology, which offers accurate segmentation and integrates with hospital systems, to a wider market.
SimBioSys president and CEO Stacey Stevens said: “At SimBioSys, we’re focused on delivering innovation that empowers clinicians to make more precise, personalised surgical decisions.
“Ricoh’s reach, reputation, and commitment to advancing surgical innovation make them an ideal partner to help bring TumorSight Viz to more clinical teams and patients.
“This partnership enables us to meet the increasing demand for tools that help improve outcomes, reduce variability, and elevate the surgical experience for both providers and patients.”
According to clinical studies, TumorSight Viz has been shown to deliver consistent performance across over 1,600 cases.
Ricoh 3D for Healthcare is a wholly owned subsidiary of Ricoh USA, developing patient-specific medical devices through centralised and point-of-care manufacturing.
The company will market TumorSight Viz as part of its effort to deliver patient-specific solutions for improved patient outcomes.
Ricoh 3D for Healthcare clinical applications director Derek Mathers said: “Breast surgeons are tasked with planning procedures that not only remove tumours effectively but also preserve quality of life for their patients.
“At Ricoh, we are committed to advancing patient-specific solutions that support physicians in this balance.
“Through our collaboration with SimBioSys, TumorSight Viz brings new clarity to surgical planning, empowering oncoplastic techniques that expand breast-conserving options and help deliver more consistent outcomes for patients.”
